BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/3/2016 5:07:00 PM | Browse: 576 | Download: 1539
 |
Received |
|
2016-03-03 09:53 |
|
Peer-Review Started |
|
2016-03-04 11:04 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-04-15 13:50 |
|
Revised |
|
2016-04-27 15:15 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-06-27 16:46 |
|
Second Decision by Editor-in-Chief |
|
2016-06-27 23:26 |
|
Final Decision by Editorial Office Director |
|
2016-07-13 12:18 |
|
Articles in Press |
|
2016-07-13 12:18 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-07-23 17:40 |
|
Publish the Manuscript Online |
|
2016-08-03 08:12 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Toshiaki Okamoto, Masahiko Koda, Kennichi Miyoshi, Takumi Onoyama, Manabu Kishina, Tomomitsu Matono, Takaaki Sugihara, Keiko Hosho, Junichi Okano, Hajime Isomoto and Yoshikazu Murawaki |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Masahiko Koda, MD, PhD, Associate Professor, Second Department of Internal Medicine, Tottori University, Nishi-cho 36-1, Yonago, Tottori 683-8504,
Japan. masakoda@grape.med.tottori-u.ac.jp |
| Key Words |
Endothelin; Ambrisentan; Steatohepatitis; Hepatic stellate cell; Hepatic fibrosis; Oxidative stress; Hepatic hydroxyproline |
| Core Tip |
Endothelin (ET) can activate hepatic stellate cells, leading to the progression of hepatic fibrosis. Fur-thermore, ET-1 may increase the inflow of free fatty acids from the fat tissue into the liver and exacerbate hepatic steatosis. Therefore, ET-1 antagonism may be a novel target for steatohepatitis. The present study showed that ambrisentan, an ET type A receptor antagonist, attenuated hepatic fibrosis by inhibiting hepatic stellate cell activation, without affecting hepatic steatosis, in a non-alcoholic steatohepatitis mouse model.
|
| Publish Date |
2016-08-03 08:12 |
| Citation |
Okamoto T, Koda M, Miyoshi K, Onoyama T, Kishina M, Matono T, Sugihara T, Hosho K, Okano J, Isomoto H, Murawaki Y. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World J Hepatol 2016; 8(22): 933-941
|
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i22/933.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i22.933 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
